Oncology

This presentation by Carol DeSantis, MPH, an epidemiologist with the American Cancer Society (ACS), covers key findings and statistics from the ACS report "Breast Cancer Facts and Figures 2013-2014."

Researchers seek improved biomarkers to distinguish between malignant and benign disease.

The United States stands to be a key player in the global oncology biosimilars market, which is predicted to generate up to $12 billion in revenue by 2020.

According to a retrospective study and a registry analysis, statin therapy may reduce the rate of local breast cancer recurrence in certain types of breast cancer.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses emerging trends in the treatment of cancer that specialty pharmacies need to be aware of.

LBH589, when used in combination with bortezomib and dexamethasone, improved progression-free survival among relapsed and refractory patients with multiple myeloma.

A genetic test in development by Micromedic may help identify patients who are likely to develop bisphosphonate-associated osteonecrosis of the jaw.

Patients with prostate cancer may benefit from bone mineral density screenings prior to initiation of therapy, researchers concluded.

Findings presented at 50th Annual Meeting of ASCO show aromatase inhibitor effective for premenopausal women when combined with ovarian function suppression.

Results from 2 large, long-term clinical trials show benefits of extended-duration treatment with tamoxifen, resulting in an update to treatment guidelines.

Patients with HIV who smoke may be at even greater risk of developing smoking-related cancers.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses developments in the treatment of lung cancer that specialty pharmacies need to be aware of.

Emerging therapies and the role of specialty pharmacies in the treatment of non-small cell lung cancer were discussed during a continuing education session at the annual Armada summit.

Gazyva is a novel anti-CD20 monoclonal antibody approved, in combination with chlorambucil, for the treatment of previously untreated chronic lymphocytic leukemia patients.

Clinical trial results show that several new combination therapies offer great promise for the treatment of challenging neuroendocrine tumors in the gastrointestinal area.

With cancer ranking third among disease states in specialty spending, there is a growing emphasis on programs that focus on cost management and patient adherence to complex medication regimens.

Assessment, interventions, and outcomes information is vital to specialty pharmacy stakeholders.

The complexities of cancer and the ever-changing medication regimens employed in its treatment call for the specialized competencies of oncology-focused pharmacies. High-touch care and oncology expertise can improve outcomes.

Oncology nurses help improve patient outcomes through their dedication and expertise.

Research suggests salaried physicians practice in the same manner as those reimbursed by fee-for-service methodology.

Primary androgen-deprivation therapy appears not to be an effective treatment for men with clinically localized prostate cancer.

Service to dispense oral oncolytics to patients shows positive results, doctors say.